Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal
Reuters
Published Apr 10, 2024 04:19PM ET
Updated Apr 10, 2024 06:01PM ET
(Reuters) -Vertex Pharmaceuticals will buy Alpine Immune Sciences (NASDAQ:ALPN) for about $4.9 billion in cash, gaining access to the biotech firm's treatment for an autoimmune disease of the kidney, the companies said on Wednesday.
The deal values each share of Alpine at $65, representing a premium of about 67% to the stock's close on Tuesday, a day before Bloomberg News reported that the company was considering options after attracting takeover interest.
Shares of Alpine were up 36% in extended trading, while Vertex (NASDAQ:VRTX) Pharma was down about 1%.
The gene therapy developer will now have access to Alpine's povetacicept, which is in mid-stage development for the treatment of IgA nephropathy (IgAN) and will be evaluated in a late-stage trial in the second half of 2024.
Povetacicept works by targeting types of proteins called BAFF and APRIL, which together contribute to the development of multiple autoimmune and antibody diseases.
IgAN, which occurs when clumps of antibodies are deposited in the kidneys, affects about 130,000 people in the United States, according to the companies.
Vertex currently has approval from the U.S. Food and Drug Administration for the treatments of cystic fibrosis — a rare genetic disorder that affects mostly the lungs — and two types of blood disorders, namely sickle cell disease and transfusion-dependent beta thalassemia.
Alpine said in a filing it may be required to pay Vertex a fee of $173 million on termination of the deal, which is approved by the boards of both companies and expected to close in the second quarter of 2024.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.